BIO invites delegations from all over the world to attend the BIO Convention in China. This event offers tremendous promise for biotech community to further its understanding of the business, R&D and policy environment in China.

Why organize a delegation to the BIO Convention in China?

The greatest advantage of organizing a delegation is to:

• Enhance understanding and sector growth in your region; promote technology exchange.
• Provide education and training opportunities for executives.
• Foster collaborations between industry, research institutes and development organizations.
• Coordinate and promote trade collaborations and economic development between enterprises in China and Rest of World.

What are the specific delegation benefits?

• One complimentary registration for the organizer, if a minimum number of delegates participate.
• Discounted registration fees for all members of the delegation.
• Recognition in conference marketing materials.
• Preference given to presentation applications from companies in the delegation.
• Additional benefits tailored to your specific needs including speaking, sponsorship and exhibition opportunities.

What are my responsibilities as an organizer?

BIO will work with delegation leaders to prepare a conference package that offers participants first-hand market information and access to decision makers in the Chinese government and local biotech community. Importantly, the BIO Customer Service team will assist you with registration pricing options, promotional tools, conference scheduling, BIO One-on-One Partnering™ tutorials and white-glove partnering support.

For more information, please contact:
Greg Meiselbach
BIO International Affairs
202-312-9289
gmeiselbach@bio.org
 

Wednesday, November 13, 2013, 2:10 p.m. - 4:25 p.m., Room 403

Organized by the China Investment Promotion Agency (CIPA)

Leader Speeches and Cluster Promotion 

2:10 p.m. – 2:25 p.m. 

Location Selection Strategy of Transnational Corporation and Environment Improvement of Economic and Technological Development Zone 

2:30 p.m. – 3:25 p.m. 
This panel will explore the different location selection standards interpreted by the overseas and domestic bio-enterprises as well as how best to collaborate with China clusters. The panel will also introduce the policy and service platform of China Biomedicine Clusters. Panelists • Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co, Ltd * Wuhan East Lake High-tech Zone * Meishan Economic Development Zone * Shanghai Newsummit Biopharma Group * Shanghai Roche Pharmaceuticals Ltd * Pfizer Investment Co, Ltd

Panelists

• Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co, Ltd
• ​Wuhan East Lake High-tech Zone
• Meishan Economic Development Zone  
• Shanghai Newsummit Biopharma Group
• Shanghai Roche Pharmaceuticals Ltd
• Pfizer Investment Co, Ltd

International Biotechnology Transfer and Industry Investment Fund 

3:30 pm – 4:25 pm 
This panel will look at current opportunities for global biotech transfer in China and what development funds are available to promote the development of the industry.

Panelists

• Dave Tapolczay, CEO, Medical Research Council Technology
• Samantha Du, Managing Director, Sequoia Capital
• Richard Lim, Partner, Omega Fund
• Syd Hanna, Partner, Elixir Ventures
• Simon Haworth, Founder, Team Kapital
• Qingdao High-Tech Industry Development Zone
• Taizhou Medical High-Tech Zone

Below is a list of the 2013 BIO Convention in China speakers.

For questions about programming, please contact Sondra Behan, Manager, Industry research and Programs, Business Development, Biotechnology Industry Organization at: sbehan@bio.org.

This page is updated frequently. Please check back regularly. 

Photo	Name and Title	Panel, Date, Time	Location
	Wen Aidong Director Drug Clinical Trial Department, the Fourth Military Medical University First Affiliated Hospital	Introduction & Clinical, Non-Clinical and CRO Panels Wednesday, November 13, 2013 9:00 a.m. - 10:55 a.m.	Room 403
	Wang Aipin General Manager/Director of Drug Safety Evaluation Center Peking Union Medical College, Chinese Academy of Medical Sciences	Introduction & Clinical, Non-Clinical and CRO Panels Wednesday, November 13, 2013 9:00 a.m. - 10:55 a.m.	Room 403
	Friedhelm Blobel, PhD President & CEO SciClone Pharmaceuticals	Dissecting China's Unmet Medical Needs Tuesday, November 12, 2013, 1:30 p.m. - 2:25 p.m.	Room 405
	James Cai Vice President of Medical Affairs Roche	Roadmap to Cultivate an Innovative Biologics Industry in China Tuesday, November 12, 2013 1:00 p.m. - 4:25 p.m.	Room 402 A & B
	Lianyong (Leon) Chen Founder & Managing Partner Frontline BioVentures	Early-Stage VC Funding in China Wednesday, November 13, 2013 1:00 p.m. - 1:55 p.m	Room 405
	Helen Chen Director & Partner L.E.K. Consulting	China's Private Health Care Industry Wednesday, November 13, 2013 11:00 a.m. - 11:55 a.m.	Room 403
	Joseph Cho Managing Director R&D-based Pharmaceutical Association Committee (RDPAC)	Roadmap to Cultivate an Innovative Biologics Industry in China Tuesday, November 12, 2013 1:00 p.m. - 4:25 p.m.	Room 402 A & B
	Chen Chunlin Chairman Shanghai Medicilon Inc	Introduction & Clinical, Non-Clinical and CRO Panels Wednesday, November 13, 2013 9:00 a.m. - 10:55 a.m.	Room 403
	Zuo Conglin General Manager Joinn Laboratories (Beijing)	Introduction & Clinical, Non-Clinical and CRO Panels Wednesday, November 13, 2013 9:00 a.m. - 10:55 a.m.	Room 403
	Jie Liu D’Elia, PhD Executive Director, Business Development Bristol-Myers Squibb	Case Studies: Partnering Models Between Chinese & Western Companies Wednesday, November 13, 2013 1:00 p.m. - 1:55 p.m.	Room 403
	Joseph Damond Senior Vice President of International Affairs, BIO	Roadmap to Cultivate an Innovative Biologics Industry in China Tuesday, November 12, 2013 1:00 p.m. - 4:25 p.m.	Room 402 A & B
	Samantha Du Managing Director Sequoia Capital China	China Biomedicine Clusters and Enterprises Investment and Collaboration Wednesday, November 13, 2013 2:10 p.m. - 4:25 p.m.	Room 403
	Alan F. Eisenberg Vice President, Federal Government Relations Celgene Corp.	Fireside Chat (Moderator) Wednesday, November 13, 2013 11:00 a.m. - 11:55 a.m.	Room 403
	James C. Greenwood President and CEO Biotechnology Industry Organization	Keynote Speaker Tuesday, November 12, 2013 9:15 a.m. - 10:25 a.m.	Auditorium
	Syd Hanna Partner Elixir Ventures	China Biomedicine Clusters and Enterprises Investment and Collaboration Wednesday, November 13, 2013 2:10 p.m. - 4:25 p.m.	Room 403
	Simon Harworth CEO Dynasty Biotechnology Limited	China Biomedicine Clusters and Enterprises Investment and Collaboration Wednesday, November 13, 2013 2:10 p.m. - 4:25 p.m.	Room 403
	Susan Herbert, PhD Head of Global BD & Strategy Merck KGaA	Fireside Chat Tuesday, November 12, 2013 11:00 a.m. - 11:55 a.m.	Room 403
	Maykin Ho, PhD Advisory Director Goldman Sachs	China's Private Health Care Industry Wednesday, November 13, 2013 11:00 a.m. - 11:55 a.m.	Room 403
	Jay Inslee Governor Washington State	Keynote Speaker Tuesday, November 12, 2013 9:15 a.m. - 10:25 a.m.	Auditorium
	Annalisa Jenkins, MBBS, MRCP Executive VP and Head of Global Research and Development  Merck KGaA	Fireside Chat Tuesday, November 12, 2013 11:00 a.m. - 11:55 a.m.	Room 403
	Weishi Li Partner Covington & Burling LLP	Case Studies: Partnering Models Between Chinese & Western Companies Wednesday, November 13, 2013 1:00 p.m. - 1:55 p.m.	Room 403
	Howard Liang, PhD Managing Director Biotechnology Equity Research, Leerink Swann	State of Capital Markets in the US Tuesday, November 12, 2013 3:00 p.m. - 3:55 p.m.	Room 405
	Richard Lim Partner Omega Fund	China Biomedicine Clusters and Enterprises Investment and Collaboration Wednesday, November 13, 2013 2:10 p.m. - 4:25 p.m.	Room 403
	Ko-Chung Lin, PhD Founder & CEO Pharmaessentia	Rare Diseases in China Wednesday, November 13, 2013 11:00 a.m. - 11:55 a.m.	Room 405
	Zeng Ling General Manager Quintiles China	Introduction & Clinical, Non-Clinical and CRO Panels Wednesday, November 13, 2013 9:00 a.m. - 10:55 a.m.	Room 403
	Mike Liu, PhD Head of Global Business Development HengRui Pharmaceuticals	Case Studies: Partnering Models Between Chinese & Western Companies Wednesday, November 13, 2013 1:00 p.m. - 1:55 p.m.	Room 403
	Peter Liu, MD Director and Founder Delta Health	China's Private Health Care Industry Wednesday, November 13, 2013 11:00 a.m. - 11:55 a.m.	Room 403
	Yuwen Liu CEO Suzhou bioBAY	Early-Stage VC Funding in China Wednesday, November 13, 2013 1:00 p.m. - 1:55 p.m	Room 405
	Gary F. Locke Ambassador of the United States of America to the People’s Republic of China	Keynote Speaker Tuesday, November 12, 2013 9:15 a.m. - 10:25 a.m.	Auditorium
	Amir Naiberg CEO Yeda Research and Development Company Ltd., The Weizmann Institute of Science	Early Stage Licensing in China - Opportunities and Challenges Wednesday, November 13, 2013 3:00 p.m. - 4:25 p.m.	Room 405
	Bruno Osterwalder, MD Senior VP, Senior Strategic Advisor Oncology, Global Drug Development and Medical Merck Serono	Dissecting China's Unmet Medical Needs Tuesday, November 12, 2013, 1:30 p.m. - 2:25 p.m.	Room 405
	Li Qing Director Development Center for Medical Science and Technology, Ministry of Health	Introduction & Clinical, Non-Clinical and CRO Panels Wednesday, November 13, 2013 9:00 a.m. - 10:55 a.m.	Room 403
	Li Shi, PhD CEO Shanghai Zerun Biotech	Company Partnerships in Vaccine Development Tuesday, November 12, 2013 11:00 a.m. - 11:55 a.m.	Room 405
	Yu Shanjiang Deputy Director Development Center for Biotech, MoST	Introduction & Clinical, Non-Clinical and CRO Panels Wednesday, November 13, 2013 9:00 a.m. - 10:55 a.m.	Room 403
	Kelvin Shao Chief Marketing Officer Shanghai NewSummit Biopharma Group	Introduction & Clinical, Non-Clinical and CRO Panels Wednesday, November 13, 2013 9:00 a.m. - 10:55 a.m.	Room 403
	Jean-Denis Shu, MD Medical Director Sanofi Pasteur, China	Company Partnerships in Vaccine Development Tuesday, November 12, 2013 11:00 a.m. - 11:55 a.m.	Room 405
	Dr. Henry Sun Vice President, Tasly Holding Group CEO, Tasly Pharmaceuticals, Inc.	Fireside Chat Tuesday, November 12, 2013 3:00 p.m. - 3:55 p.m.	Room 403
	Dave Tapolczay CEO Medical Research Council Technology	China Biomedicine Clusters and Enterprises Investment and Collaboration Wednesday, November 13, 2013 2:10 p.m. - 4:25 p.m.	Room 403
	David Thomas, CFA Director, Industry Research & Analysis BIO	State of Capital Markets in the US Tuesday, November 12, 2013 3:00 p.m. - 3:55 p.m.	Room 405
	Hongguang Wang Advisor, Deputy Director Chinese Academy of Science and Technology for Development (CASTED), Ministry of Science and Technology( M0ST)	Roadmap to Cultivate an Innovative Biologics Industry in China Tuesday, November 12, 2013 1:00 p.m. - 4:25 p.m.	Room 402 A & B
	Jonathan Wang, PhD Senior Managing Director OrbiMed Healthcare Fund Management	Early-Stage VC Funding in China Wednesday, November 13, 2013 1:00 p.m. - 1:55 p.m	Room 405
	Lawrence Wang, MD Managing Director Primavera Capital Group	China's Private Health Care Industry Wednesday, November 13, 2013 11:00 a.m. - 11:55 a.m.	Room 403
	Zheng Weiyi General Manager Nanjing Kangke Nuode Pharmaceutical Technology Co, Ltd	Introduction & Clinical, Non-Clinical and CRO Panels Wednesday, November 13, 2013 9:00 a.m. - 10:55 a.m.	Room 403
	Russell Wilson Senior Vice President, Business Development Novavax	Dissecting China's Unmet Medical Needs Tuesday, November 12, 2013, 1:30 p.m. - 2:25 p.m.	Room 405
	Asish K. Xavier, PhD Vice President, Venture Investments J&J Development Corporation	State of Capital Markets in the US Tuesday, November 12, 2013 3:00 p.m. - 3:55 p.m.	Room 405
	Wang Xiaodong, PhD Director and Investigator National Institute of Biological Sciences (NIBS)	Fireside Chat Tuesday, November 12, 2013 1:30 p.m. - 2:55 p.m.	Room 403
	Wang Xin Chairman Beijing Bionovo	Introduction & Clinical, Non-Clinical and CRO Panels Wednesday, November 13, 2013 9:00 a.m. - 10:55 a.m.	Room 403
	Grace Xu Vice President, Product Development & Strategic Planning Bristol-Myers Squibb	Dissecting China's Unmet Medical Needs Tuesday, November 12, 2013, 1:30 p.m. - 2:25 p.m.	Room 405
	Guo Yajun Director  National Engineering Center for Antibody Drug Research	Introduction & Clinical, Non-Clinical and CRO Panels Wednesday, November 13, 2013 9:00 a.m. - 10:55 a.m.	Room 403
	Zhao Yajun Director General China Center for Pharmaceutical International Exchange	Keynote Speaker  Tuesday, November 12, 2013 9:15 a.m. - 10:25 a.m.	Auditorium
	Huang Yangbin Chief Technology Officer Shanghai Newsummit Biopharma Group	Introduction & Clinical, Non-Clinical and CRO Panels Wednesday, November 13, 2013 9:00 a.m. - 10:55 a.m.	Room 403
	Wang Yinxiang, PhD CEO and Chief Scientific Officer Zhejiang Beta Pharma	Fireside Chat Wednesday, November 13, 2013 11:00 a.m. - 11:55 a.m.	Room 405
	Michael Yu CEO Innovent Biologics	Roadmap to Cultivate an Innovative Biologics Industry in China Tuesday, November 12, 2013 1:00 p.m. - 4:25 p.m.	Room 402 A & B
	Jerry Zeldis, MD, PhD Chief Executive Officer Celgene Global Health and Chief Medical Officer, Celgene Corporation	Rare Diseases in China Wednesday, November 13, 2013 11:00 a.m. - 11:55 a.m.	Room 405
	Jimmy Zhang, PhD Managing Director, MSD Early Investments Greater China, Merck & Co.	Early-Stage VC Funding in China Wednesday, November 13, 2013 1:00 p.m. - 1:55 p.m	Room 405
	Nick Zhang, PhD China General Manager, Senior Vice President Frontage Lab	Dissecting China's Unmet Medical Needs Tuesday, November 12, 2013, 1:30 p.m. - 2:25 p.m.	Room 405
	Bian Zhenjia Assistant Minister China Food and Drug Administration (CFDA)	Keynote Speaker Tuesday, November 12, 2013 9:15 a.m. - 10:25 a.m.	Auditorium
	Xiaoming Zou, PhD, Chief Business Officer, Eddingpharm	Case Studies: Partnering Models Between Chinese & Western Companies Wednesday, November 13, 2013 1:00 p.m. - 1:55 p.m.	Room 403